Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | VHL | P40337 | 1/20 | 0.36 |
| ▸ | ELOC | Q15369 | 1/20 | 0.36 |
| ▸ | ELOB | Q15370 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10366338 | 0.89 | ALDH1A1 (0.45) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL7235884 | 0.86 | ALDH1A1 (0.38) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL13392736 | 0.78 | ALDH1A1 (0.35) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL2798056 | 0.78 | ALDH1A1 (0.40) | ALDH1A1HPGDKDM4EPTGS2RAB9A | |
| SCHEMBL8244272 | 0.78 | RYR2 (0.55) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL3939490 | 0.74 | LMNA (0.36) | ALDH1A1MEN1MAPTKMT2AVHL | |
| SCHEMBL17227584 | 0.73 | VHL (0.34) | ALDH1A1HPGDKDM4EVHLELOC | |
| SCHEMBL10368454 | 0.73 | IGF1R (0.55) | HPGDRAB9ATDP1 | |
| SCHEMBL9607633 | 0.73 | KDM4E (0.55) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL3328663 | 0.73 | HDAC1 (0.55) | ALDH1A1MAPTKMT2AKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125455-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, Receptor ligands | VERNALIS RESEARCH LIMITED | 2008-05-29 | — | — | US | disclosed |
| US-20080114018-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2008-05-15 | — | — | US | disclosed |
| US-20080090858-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2008-04-17 | — | — | US | disclosed |
| US-7323473-B2 | Administering (S)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine; serotonin receptor antagonists (5HT/5HT2C) for treatment of obesity | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323487-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323486-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20070105889-A1 | Condensed indoline derivatives and their use as 5HT , in particular 5hHT2c, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-20070099981-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-03 | — | — | US | disclosed |
| US-20070099980-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-03 | — | — | US | disclosed |
| US-7173056-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| CN-1711243-A | 2-pyridone derivatives as inhibitors of neutrophil elastase | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | CN | disclosed |
| US-6962939-B1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2005-11-08 | — | — | US | disclosed |
| EP-1202964-B1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RES LTD (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20050197380-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-09-08 | — | — | US | disclosed |
| US-20050192334-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-09-01 | — | — | US | disclosed |
| US-20050187282-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-08-25 | — | — | US | disclosed |
| EP-1562902-A1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004043924-A1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | WO | disclosed |
| EP-1202964-A1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012602-A1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090858-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | ALDH1A1 1748/4885MEN1 765/4885GAA 4780/4885 |
| US-20050197380-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | ALDH1A1 1748/4885MEN1 765/4885GAA 4780/4885 |
| US-20050192334-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | ALDH1A1 1748/4885MEN1 765/4885GAA 4780/4885 |
| US-20080125455-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, Receptor ligands | HTR2C, HTR2A, HTR1A | ALDH1A1 1741/4885MEN1 763/4885GAA 4778/4885 |
| US-20080114018-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | ALDH1A1 1748/4885MEN1 765/4885GAA 4780/4885 |
| US-20050187282-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | HTR2C, HTR2A, HTR1A | ALDH1A1 1748/4885MEN1 765/4885GAA 4780/4885 |
| US-20070099980-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | ALDH1A1 1748/4885MEN1 765/4885GAA 4780/4885 |
| US-20070105889-A1 | Condensed indoline derivatives and their use as 5HT , in particular 5hHT2c, receptor ligands | HTR2C, HTR2A, HTR5A | ALDH1A1 1407/4885MEN1 1151/4885GAA 4743/4885 |
| US-20070099981-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | ALDH1A1 1748/4885MEN1 765/4885GAA 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.